Diabetes, Presentation and Process Improvement

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Diabetes

Presentation

Process Improvement

Developing a first-in-class small molecule drug for inflammatory disease

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Drug Development

Drug Development Immunity Immunization Pharmaceutical Companies

Drug development trends: insight from Thermo Fisher’s Anil Kane

European Pharmaceutical Review

DECEMBER 1, 2023

They could be for the oncology space, including different types of cancers, central nervous system indications such as Alzheimer’s, Parkinson’s and epilepsies, and also the most common indications for diabetes and other metabolic disorders. Also, we can expect to see the utilisation of digital technologies for predictive modelling.

Drug Development

Drug Development Dosage Diabetes Process Improvement

Pharmacist Digest

Developing a first-in-class small molecule drug for inflammatory disease

Drug development trends: insight from Thermo Fisher’s Anil Kane

Stay Connected